We are live on ! Find out more
49.32 USD
-0.10
0.2%
At close Updated Sep 4, 4:00 PM EDT
Pre-market
After hours
49.32
0.00
0%
1 day
-0.2%
5 days
-0.88%
1 month
-2.14%
3 months
40.39%
6 months
14.72%
Year to date
21.72%
1 year
-9.82%
5 years
-61.66%
10 years
17.01%
 

About: Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.

Employees: 3,900

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 47.4%
Neutral 52.6%
Negative 0%
Positive
Zacks Investment Research
8 days ago
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Neutral
Business Wire
10 days ago
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
Positive
Seeking Alpha
18 days ago
CONMED Corporation: Organic Growth Is Masked By Divestitures
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.
CONMED Corporation: Organic Growth Is Masked By Divestitures
Positive
Zacks Investment Research
19 days ago
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
Neutral
Zacks Investment Research
19 days ago
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
Positive
Zacks Investment Research
19 days ago
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
Neutral
Zacks Investment Research
19 days ago
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
Positive
Zacks Investment Research
1 month ago
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
Neutral
Seeking Alpha
1 month ago
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
1 month ago
CONMED Q2 Earnings Call Highlights
CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company's exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management's expectations.
CONMED Q2 Earnings Call Highlights
Price charts implemented using Lightweight Charts™